

Controlled Clinical Trials

DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 16, Number 1, 1995

JANET WITTES

Editorial From the Editor

1

GERRY OSTER, GERALD M. BOROK, JOSEPH MENZIN, JOSEPH F. HEYSE,
ROBERT S. EPSTEIN, VIRGINIA QUINN, VICTOR BENSON, R. JAMES DUDL,
AND ARNOLD EPSTEIN

A Randomized Trial to Assess Effectiveness and Cost in Clinical Practice:
Rationale and Design of the Cholesterol-Reduction Intervention
Study (CRIS)

3

MARK S. KAMLET, NANCY PAUL, JOEL GREENHOUSE, DAVID KUPFER,
ELLEN FRANK, AND MARTCIA WADE

Cost Utility Analysis of Maintenance Treatment for Recurrent Depression

17

CLARENCE E. DAVIS, WILLIAM B. APPELGATE, DAVID J. GORDON,
R. CAROLYN CURTIS, AND MAUREEN McCORMICK

An Empirical Evaluation of the Placebo Run-in

41

JEFFREY D. HORBAR, KATHLEEN A. LEAHY, FOR THE INVESTIGATORS
OF THE VERMONT-OXFORD TRIALS NETWORK

An Assessment of Data Quality in the Vermont-Oxford Trails
Network Database

51

DAVID MOHER, ALEJANDRO R. JADAD, GRAHAM NICHOL,
MARIE PENMAN, PETER TUGWELL, AND SHARON WALSH

Assessing the Quality of Randomized Controlled Trials:

An Annotated Bibliography of Scales and Checklists

62

THE SvO₂ COLLABORATIVE GROUP

The SvO₂ Study: General Design and Results of the Feasibility Phase of
a Multicenter, Randomized Trial of Three Different Hemodynamic
Approaches and Two Monitoring Techniques in the Treatment of Critically
Ill Patients

74

Announcement

88

Volume 16, Number 2, 1995

MYLAN C. COHEN, CAROL McKENNA, STANLEY M. LEWIS, AND
JAMES E. MULLER

Requirements for Controlled Clinical Trials of Preoperative Cardiovascular
Risk Reduction

89

DAVID M. ZUCKER, EDWARD LAKATOS, LARRY S. WEBBER,
DAVID M. MURRAY, SONJA M. McKINLAY, HENRY A. FELDMAN,
STEVE H. KELDER, AND PHILIP R. NADER, for the CATCH Study Group
Statistical Design of the Child and Adolescent Trial for Cardiovascular
Health (CATCH): Implications of Cluster Randomization

96

PING-YU LIU AND STEVE DAHLBERG	
Design and Analysis of Multiarm Clinical Trials with Survival Endpoints	119
JOHAN BRING	
Letter to the Editor Stopping a Clinical Trial Early Because of Toxicity: The Bayesian Approach	131
GEORGE W. COMSTOCK	
Letter to the Editor Note on Large, Simple, Widely Representative Trials	133
JANET WITTES	
List of Reviewers	135
Announcements	136

Volume 16, Number 2, 1995

Supplement

Data Management for Multicenter Studies: Methods and Guidelines

Preface	<i>Barbara S. Hawkins</i>	vii
Contributors		viii
Introduction	<i>Ruth McBride and Stephen W. Singer</i>	1S
Functions and Organization of Coordinating Centers for Multicenter Studies		4S
<i>Brent A. Blumenstein, Kenneth E. James, Bonnie K. Lind, and Herman E. Mitchell</i>		

INTRODUCTION	4S
PRIMARY AND SECONDARY MISSIONS	4S
TYPES OF MULTICENTER STUDIES	6S
Single Study in a Single Disease	6S
Multiple Studies of a Single Disease	7S
Multiple Studies and Multiple Diseases	7S
Single Study of Multiple Diseases	8S
RELATIONSHIP OF THE COORDINATING CENTER TO OTHER STUDY COMPONENTS	8S
Field Sites	8S
Resource Centers	11S
Central Laboratories	12S
Expert Interpretation Services	12S
Drug Distribution Services	12S
Intervention Management Services	12S
Scientific Management and Leadership	13S
Study Sponsor	14S
COORDINATING CENTER FUNCTIONS, ORGANIZATION, AND PERSONNEL	15S
Statistical Support	16S
Systems Coordination	19S
Computer Systems Support and Programming	20S
Creation, Acquisition, and Management of Study Materials	23S
Training and Monitoring	24S

Data Operations	25S
Administrative Support	26S
DATA ANALYSIS AND PUBLICATION	26S
DISCUSSION	27S
REFERENCES	28S
Approaches to Data Management	30S
<i>Eleanor T. McFadden, Frances LoPresti, Lance R. Bailey, Ellis Clarke, and Patricia C. Wilkins</i>	
INTRODUCTION	30S
REQUIREMENTS ANALYSIS	30S
Objectives	30S
Protocol and Project Scope	31S
Functional Description of Data Interactions	32S
Database Storage Requirements	33S
Validation Criteria	34S
Regulatory Requirements	34S
Staffing and Organizational Constraints	35S
CENTRAL VERSUS DISTRIBUTED DATA PROCESSING	35S
Data Intensity	36S
Data Dispersion	36S
Volatility of Protocol and Data Collection Instruments	36S
Environment of the Coordinating Center and Field Sites	37S
Need for Local Functions	37S
Timeliness Issues	38S
Facsimile Use in the Centralized Model	38S
Computer-Assisted Data Collection in the Distributed Model	38S
Choosing Functions to Be Distributed	39S
Differences in Architecture and Design	40S
Differences in Implementation Schedule	41S
Data Transmission Choices	41S
Choice Among Options	42S
SOFTWARE AND HARDWARE SELECTION	42S
Choosing Database Management Software	42S
Database Types and Models	43S
Relational Model	43S
Hierarchical Model	44S
Other Models	45S
Choice of a Database Model	46S
Operating System	47S
Hardware Selection	48S
DEVELOPMENT, PROJECT MANAGEMENT, AND REPORTING TOOLS	49S
COMMUNICATIONS	49S
Facsimile Transmission	50S
Voice Transmission	50S
Courier and Mail Services	50S
Electronic Data Transfer	50S
Public Telephone System	50S

Public Networks	51S
Electronic Mail	51S
Error Rates and Transmission Integrity	51S
COMPUTER SECURITY	52S
Internal Access	52S
External Access	52S
Malicious Intent	52S
Computer Viruses and Trojan Horses	53S
DATABASE MANAGEMENT SYSTEM	
ADMINISTRATION	53S
Database Design	54S
Participant Identifier	54S
Key Fields	54S
Data Redundancy	54S
Data Format	54S
Administrative Data	55S
Data Security	55S
Data Integrity and Transaction Processing	55S
Backup and Recovery	56S
Audit Trails	56S
Performance Optimization	57S
CONTROLLING PARTICIPANT ENROLLMENT	
AND TREATMENT ASSIGNMENT	57S
Telephone Call-in Systems	58S
Envelope Systems	58S
Facsimile or Telecopier Systems	59S
Voice Information Systems	59S
Distributed Systems	60S
Summary of Enrollment and Treatment Assignment	
Systems	60S
OTHER SOFTWARE DEVELOPMENT OPTIONS	60S
Appointment Schedules	61S
Calendars and Reminders	61S
Local Reports	61S
Data Queries	61S
Auto-Encoding Dictionaries	62S
Inventory Systems	62S
Summary	62S
CONCLUSIONS	62S
REFERENCES	63S
Data Collection and Transcription	66S
<i>James D. Hosking, M. Marvin Newhouse,</i>	
<i>Anna M. Bagniewska, and Barbara S. Hawkins</i>	
INTRODUCTION	66S
DATA COLLECTION	66S
Identifying the Data to Be Collected	66S
Forms Design	67S
Objectives of Forms Design	68S
Standardization of Data Collection Forms	68S
Guidelines for Forms Design	69S
Guidelines for Item Content and Format	70S

Guidelines for Physical Format	71S
Essential Identifying Information for a Form	73S
Guidelines for Identifiers	73S
Item Identifiers	75S
Forms Review and Testing	76S
Forms Production	76S
Organizing Items into Forms	77S
Translating Forms	78S
Review by the Office of Management and Budget	78S
Reproduction and Binding	79S
Producing Copies of Completed Forms	79S
Revisions to Data Collection Forms	80S
Procedures for Data Recording	82S
DATA CODING	84S
When Is Coding Necessary or Desirable?	84S
Recording of Responses Requiring Coding	84S
Who Should Code Information?	86S
When Should Coding Take Place?	88S
Level of Detail Required When Coding	88S
Standard Coding Dictionaries	90S
Guidelines for Developing Special Purpose Codes	90S
DATA ENTRY METHODS AND TOOLS	91S
Introduction	91S
Organization of Data Entry	91S
Desirable Functions and Capabilities of Data	
Entry Systems	91S
Display and Flow Capabilities	91S
Data Edits During Entry	93S
Missing or Special Value Codes	97S
Rekey Verification	97S
Error Rates	98S
Corrections	99S
Interface to Other Software	99S
Alternatives to Key Entry	100S
REFERENCES	101S

Data Quality Assurance, Monitoring, and Reporting	104S
<i>Jennifer J. Gassman, Walter W. Owen, Timothy E. Kuntz,</i>	
<i>Jeffrey P. Martin, and William P. Amoroso</i>	

INTRODUCTION	104S
ROUTINE AUTOMATED EDITS	109S
Guiding Principles	109S
Selection of Data for Checking	110S
Types of Data Element Checks	110S
Routine Data Edits at the Key Entry Level	112S
Routine Data Edits at the Central Database Level	112S
Checks on Database Quality During Data Analysis	
and Reporting	114S
Handling Anomalous Data	114S

RESOLVING DISCREPANCIES: DATA QUERIES AND RESPONSES	115S
Content of Data Queries	115S
Communicating with Field Sites About Data Anomalies	117S
Field Site Responses to Queries	117S
Correction of the Database	118S
Tracking Corrections and Other Changes to the Database	120S
MONITORING ACCURACY, CURRENCY, AND INTEGRITY OF THE DATABASE	120S
Monitoring Completeness and Currency of the Database	120S
Monitoring Timeliness of Data Submission	121S
Monitoring Accuracy of Data Collection	121S
Monitoring Accuracy of Data Entry	122S
Monitoring Accuracy of Data Transmission	123S
Monitoring Quality of the Data Management System	123S
Monitoring Delays in Responses to Queries	124S
DATA QUALITY REPORTS	125S
Discrepancies and Error Corrections	125S
Accuracy, Currency, and Completeness of the Study Database	125S
Resource Center Quality Monitoring and Performance Reports	126S
Coordinating Center Quality Monitoring and Reports	127S
PROMOTION OF TIMELY AND ACCURATE DATA COLLECTION AND REPORTING	128S
Training and Certification	128S
Field Site Management Aids and Reminders	129S
Considerations for Design and Production	129S
Scheduling Aids	130S
Missing Materials Reminders	131S
Other Aids	131S
Site Visits and Record Audits	131S
Visits to Field Sites	131S
Site Visits to Resource Centers	132S
Site Visits to the Coordinating Center	133S
SUMMARY AND CONCLUSIONS	133S
REFERENCES	134S

Interim Reports, Participant Closeout, and Study Archives <i>Ruth McBride and Stephen W. Singer</i>	137S
---	------

INTRODUCTION	137S
INTERIM REPORTS	137S
Performance Monitoring Reports	138S
Treatment Effects Monitoring Reports	141S

General Considerations for Design of Reports	143S
Production of Reports	148S
Selecting the Dataset	149S
Preparations for a Database Freeze	151S
Creating the Interim Analysis Dataset	151S
Generating the Contents: Reporting Tools and Software	153S
Checking the Report	154S
PARTICIPANT CLOSEOUT	155S
Collection of Additional Information at Participant Closeout Contacts	155S
Final Validation, Correction, and Closure of the Study Database	157S
Issues Related to Early Termination of a Clinical Trial	158S
Dissemination of Study Findings	160S
STUDY ARCHIVES	161S
Archives Established and Maintained During Study Execution	163S
Archives Established at Study Completion	163S
CONCLUSION	165S
REFERENCES	166S
Appendix A: Glossary	168S
Appendix B: Studies Cited and Sources of Information	175S
Appendix C: Reviewers for This Issue	179S

Volume 16, Number 3, 1995

GENELL L. KNATTERUD AND CURTIS L. MEINERT	
A Tribute to Christian Robert Klimt	139
NOWAMAGBE A. OMOIGUI AND ERIC J. TOPOL	
Observational versus Randomized Medical Device Testing Before and After Market Approval—The Atherectomy-versus-Angioplasty Controversy	143
POLLY FEIGL, BRENT BLUMENSTEIN, IAN THOMPSON, JOHN CROWLEY, MICHAEL WOLF, BARNETT S. KRAMER, CHARLES A. COLTMAN, JR., OTIS W. BRAWLEY, AND LESLIE G. FORD	
Design of the Prostate Cancer Prevention Trial (PCPT)	150
SUNG C. CHOI, TERESA P. GERMANSON, AND THOMAS Y. BARNES	
A Simple Measure in Defining Optimal Strata in Clinical Trials	164
PETER FAYERS, DELLA GIBSON, AND JEAN MOSSMAN	
UKCCCR Register of U.K. Cancer Trials	172
HORST J. KOCH	
Letter to the Editor	182
WILLIAM M. VOLLMER, MOLLY L. OSBORNE, STEPHANIE HERTERT, AND A. SONIA BUIST	
In Response to Dr. Koch's Letter	184
Books Received	185
Announcement	186

**Volume 16, Number 3, 1995
Supplement**

Letter from the President	1S
Calendar of Program	3S
Abstracts: Sixteenth Annual Meeting of the Society of Clinical Trials	33S
Author Index	142S

Volume 16, Number 4, 1995

Workshop on "David Byar: An Accidental Career"

David P. Byar, MD	187
SYLVAN B. GREEN	
David Byar: An Accidental Career	189
SAMUEL W. GREENHOUSE	
Dave Byar as a Student	191
MARVIN A. SCHNEIDERMAN	
David Byar as a Supervisee	193
NATHAN MANTEL	
David Byar as a Collaborator	197
STEVEN PIANTADOSI	
David Byar as a Teacher	202
Edited Composite of Floor Discussions Following Presentations by S. Greenhouse, M. Schneiderman, N. Mantel, and S. Piantadosi	212
LINCOLN E. MOSES	
Some of David Byar's Work: In Appreciation	216
MITCHELL H. GAIL	
Dave Byar's Contribution to Epidemiology	230
ROSS L. PRENTICE	
On the Role, Design, and Analysis of Disease Prevention Trials	249
PETER ARMITAGE	
David Byar's Approach to the Analysis of Survival Data with Covariates	259
MARK HARRINGTON	
In Memoriam: David Byar as an AIDS Activist	270

Volume 16, Number 4, 1995

Supplement

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial

Contributors	viii
TRUDY L. BUSH, MARK A. ESPELAND, AND IRMA MEBANE-SIMS	
Overview	1S
MARK A. ESPELAND, TRUDY L. BUSH, IRMA MEBANE-SIMS, MARCIA L. STEFANICK, SUSAN JOHNSON, ROGER SHERWIN, AND MYRON WACLAWIW	
Rationale, Design, and Conduct of the PEPI Trial	3S

SUSAN JOHNSON, IRMA MEBANE-SIMS, PATRICIA E. HOGAN, AND DIANE B. STOY	
Recruitment of Postmenopausal Women in the PEPI Trial	20S
PETER D. WOOD, GERALD KESSLER, KENNETH LIPPEL, MARCIA L. STEFANICK, CAROL H. WASILAUSKAS, AND H. BRADLEY WELLS	
Physical and Laboratory Measurements in the PEPI Trial	36S
VALERY T. MILLER, ROBERT L. BYINGTON, MARK A. ESPELAND, ROBERT LANGER, ROBERT MARCUS, SALLY SHUMAKER, AND MICHAEL P. STERN	
Baseline Characteristics of the PEPI Participants	54S
References	66S
Appendix I: Key Clinic Personnel	73S
Appendix II: Sample Consent Form	76S
 Volume 16, Number 5, 1995	
LAURENCE S. FREEDMAN, RICHARD SIMON, MARY A. FOULKES, LAWRENCE FRIEDMAN, NANCY L. GELLER, DAVID J. GORDON, AND RICHARD MOWERY	
Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993 – The Perspective of NIH Clinical Trialists	277
JEAN-PIERRE BOISSEL, FRANÇOIS GUEYFFIER, AND MARGARET HAUGH	
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993 – The Perspective of NIH Clinical Trialists"	286
MARTIAL G. BOURASSA	
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993 – The Perspective of NIH Clinical Trialists"	289
SHEILA M. GORE	
Inclusion of Women and Minorities in Clinical Trials	290
OTIS W. BRAWLEY	
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993 – The Perspective of NIH Clinical Trialists"	293
A. SONIA BUIST AND MERWYN R. GREENLICK	
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993 – The Perspective of NIH Clinical Trialists"	296
WILLIAM D. FRASER	
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993 – The Perspective of NIH Clinical Trialists"	299
WENDY BALDWIN	
Impact of the NIH Inclusion Guidelines	300
ROBERT F. WOOLSON, MARTHA F. JONES, WILLIAM R. CLARKE, AND JAMES C. TORNER	
Discussion of "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993 – The Perspective of NIH Clinical Trialists"	301
CURTIS L. MEINERT	
Comments of NIH Clinical Trials Valid Analysis Requirement	304

STEVEN PLANTADOSI	
Commentary Regarding "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists"	307
LAURENCE S. FREEDMAN, RICHARD SIMON, MARY A. FOULKES, LAWRENCE FRIEDMAN, NANCY L. GELLER, DAVID J. GORDON, AND RICHARD MOWERY	
Response to Discussants' Letters	310
JOSEPH B. KADANE	
Prime Time for Bayes	313
JEAN-PIERRE BOISSEL, ISABELLE DURIEU, PASCAL GIRARD, PATRICE NONY, FRANCK CHAUVIN, AND MARGARET HAUGH	
Dose-Ranging Trials: Guidelines for Data Collection and Standardized Descriptions	319
WILLIAM G. HENDERSON, THOMAS MORITZ, STEVEN GOLDMAN, JACK COPELAND, AND GULSHAN SETHI	
Use of Cumulative Meta-Analysis in the Design, Monitoring, and Final Analysis of a Clinical Trial: A Case Study	331
MIRIAM C. CHERNOFF, MINGZHU WANG, JENNIFER J. ANDERSON, AND DAVID T. FELSON	
Problems and Suggested Solutions in Creating an Archive of Clinical Trials Data to Permit Later Meta-Analysis: An Example of Methotrexate Trials in Rheumatoid Arthritis	342
TIE-HUA NG	
Conventional Null Hypothesis Testing in Active Control Equivalence Studies	356
TOSIYA SATO	
Letter to the Editor	359

Volume 16, Number 6, 1995

STEPHEN W. SINGER AND CURTIS L. MEINERT	
Format-Independent Data Collection Forms	363
NEIL R. POWE AND ROBERT I. GRIFFITHS	
The Clinical-Economic Trial: Promise, Problems, and Challenges	377
JOANNA H. SHIH	
Sample Size Calculation for Complex Clinical Trials with Survival Endpoints	395
DAVID L. DEMETS, THOMAS R. FLEMING, RICHARD J. WHITLEY, JAMES F. CHILDRESS, SUSAN S. ELLENBERG, MARY FOULKES, KENNETH H. MAYER, JUDITH O'FALLON, RICHARD B. POLLARD, JAMES J. RAHAL, MERLE SANDE, STEPHEN STRAUS, LEROY WALTERS, AND PATRICIA WHITLEY-WILLIAMS	
The Data and Safety Monitoring Board and Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials	408
TERENCE A. GERACE, VALERIE ANNE GEORGE, AND ISABEL G. ARANGO	
Response Rates to Six Recruitment Mailing Formats and Two Messages about a Nutrition Program for Women 50-79 Years Old	422

SAMUEL CHARACHE, MICHAEL L. TERRIN, RICHARD D. MOORE, GEORGE J. DOVER, ROBERT P. MCMAHON, FRANCA B. BARTON, MYRON WACLAWIW, SUSAN ECKERT, AND INVESTIGATORS OF THE MULTICENTER STUDY OF HYDROXYUREA	
Design of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia	432
MICHAEL T. STEVENS AND THOMAS J. URYNIAK	
Response to S.J. Day Letter	447
JAMES ROCHON	
Letter to the Editor: Sample Size Calculations for Repeated Measures Experiments	449
JOHN E. OVERALL AND SUZANNE R. DOYLE	
Letter to the Editor: Comment on the Substitution of z for t and on Hotelling's T^2 for Repeated Measurements	451
BRENT A. BLUMENSTEIN	
Letter to the Editor: Medical Research Data	453
DELLA GIBSON, ANGELA J. HARVEY, AND MAHESH K.B. PARMAR	
Letter to the Editor: Response to Dr. Blumenstein's Letter	455
WILLIAM R. FAIRWEATHER	
Book Review: <i>Drug Safety Assessment in Clinical Trials</i>	456
BARBARA S. HAWKINS	
Book Review: <i>Clinical Data Management</i>	458
Volume 16 Author Index	460
Volume 16 Subject Index	462
Volume Contents	